Neuron specific enolase,p53蛋白和proliferating-cell nuclear antigen在肺癌组织中的表达及意义

目的：研究神经元特异性烯醇化酶（neuronspecificenolase，NSE）的表达，与p53蛋白和增殖细胞核抗原（prolif－erating－cellnuclearantigen，PCNA）表达的关系及意义．方法：用特异性鼠抗人单克隆抗体，按LSAB免疫组织化学方法检测石蜡包埋的肺癌标本中NSE，p53蛋白和PCNA的表达．结果：在小细胞性肺癌（SmallCellLungCancer，SCLC）中，NSE阳性表达者，PCNA标记指数（LabellingIndex，LI）高于NSE阴性者，而p53蛋白的表达与NSE的表达无关．在非小细胞性肺癌（non－smallcelllungcancr，non－SCLC）中，p53蛋白的表达和PCNALI均与NSE的表达无关．结论：在SCLC的发生及发展过程中，神经内分泌功能可能起了部分作用．而p53抑癌基因在SCLC的发生中并不起着重要的作用．

Mast cell density and the context of clinicopathological parameters and expression of p185,estrogen receptor,and proliferating cell nuclear antigen in gastric carcinoma

AIM:To investigate the relationship between the mast cell density(MCD)and the context of clinicopathological parameters and expression of p185,estrogen receptor(ER), and proliferating cell nuclear antigen(PCNA)in gastric carcinoma. METHODS:Mast cell,p185,ER,and PCNA were detected using immunohistochemical S-P labeling method.Mast cell was counted in tissue of gastric carcinoma and regional lymph nodes respectively,and involved lymph nodes(ILN)were examined as usual. RESULTS:MCD was significantly related to both age and depth of penetration(x^2=4.688,P<0.05 for age and x^2=9.350, P<0.01 for depth of penetration)between MCD>21/0.03 mm^2 and MCD≤21/0.03 mm^2 in 100 patients;MCD in 1-6 ILN group patients was significantly higher than that in 7-15 ILN or>15 ILN group patients(u=6.881,8.055,P<0.01); There were significant differences intergroup in positive expression rate of p185,ER and PCNA between MCD>21/ 0.03 mm^2 and MCD≤21/0.03 mm^2 in 100 patients. CONCLUSION:Mast cell may have effect on inhibiting invasive growth of tumor,especially in the aged patients; The number of mast cells,in certain degree,may predicate the number of involved lymph nodes,which is valuable for assessment of prognosis;MCD was related to the expression of p185,ER,and PCNA in gastric carcinoma.It suggests that mast cell accumulation may inhibit the proliferation and the dissemination of the gastric carcinoma. INTRODUCTION Recently,many studies have reported on the association of mast cell with various tumorst.In several malignancies,mast cell has been found to correlate with growth,penetration and prognosis of tumor.Therefore,our study was undertaken to investigate the relationship between the mast cell density (MCD)and the context of clinicopathological parameters and expression of p 185,estrogen receptor(ER),and proliferating cell nuclear antigen(PCNA)in gastric carcinoma.

Influence of norcantharidin on proliferation,proliferation-related gene proteins prolifera-ting cell nuclear antigen and Ki-67 of human gallbladder carcinoma GBC-SD cells

BACKGROUND: Gallbladder carcinoma is a highly lethal and aggressive disease with early metastasis, strong invasion and poor prognosis. Most patients with this disease are at the advanced and un-resectable stage and should be consi- dered for palliative treatment such as chemotherapy and ra- diotherapy. Unfortunately, reports of chemotherapy and radiotherapy for gallbladder carcinoma are disappointing. We investigated the influence of norcantharidin (NCTD) on proliferation, proliferation-related gene proteins PCNA and Ki-67 of human gallbladder carcinoma GBC-SD cells in vitro. METHODS: GBC-SD cell lines of human gallbladder carci- noma were cultured by the cell culture technique. The ex- periment was divided into NCTD group and control group. The tetrazolium-based colorimetric assay was used to evaluate cell growth. The streptavidin-biotin complex method was used to determine the expressions of prolifera- tion-related gene proteins PCNA and Ki-67 of human gall- bladder carcinoma GBC-SD cells. RESULTS: NCTD inhibited the growth and proliferation of GBC-SD cells from 10 mg/L or after 6 hours in a dose- and time-dependent manner, with the IC50 value of 56.18 μg/ ml at 48 hours. After treatment with NCTD, the expression of PCNA (0.932 ±0.031 vs. 0.318 ±0.023, P<0.001) and Ki-67 (0.964 ±0.092 vs. 0.297 ±0.018, P<0.001) proteins were decreased significantly. CONCLUSION: NCTD inhibits the proliferation of human gallbladder carcinoma GBC-SD cells in vitro and the expres- sion of their proliferation-related gene proteins PCNA and Ki-67.

基质金属蛋白酶12在胃癌组织、细胞中的表达及对裸鼠移植瘤生长的影响实验研究

目的:观察基质金属蛋白酶12(MMP-12)在胃癌组织和胃癌细胞株SGC-7901中的表达及对裸鼠移植瘤生长的影响。方法:收集胃癌患者42例,手术后留取肿瘤组织和距肿瘤边缘>3 cm的正常胃黏膜组织,应用免疫组化EnVision法检测MMP-12的表达。合成sh-MMP12质粒,应用慢病毒载体转染胃癌细胞株SGC-7901,设为sh-MMP12组,同时设立未行任何干预的细胞为空白对照组(NC组),应用Western blot法检测MMP-12和增殖细胞核抗原(PCNA)蛋白的表达,应用实时荧光定量PCR(RT-qPCR)检测MMP-12和PCNA mRNA的表达。选择4~5周龄的BALB/C雌性裸鼠5只,分别将sh-MMP12组和NC组细胞悬液注射于同一只裸鼠的左右两侧腋下(左侧为sh-MMP12组,右侧为NC组),间隔7 d测量并记录肿瘤体积,28 d后处死小鼠对瘤体称重。结果:免疫组化结果显示,胃癌组织MMP-12阳性率高于正常胃黏膜组织,胃癌组织MMP-12和PCNA表达呈正相关(均P<0.05)。Western blot结果显示,sh-MMP12组MMP-12和PCNA蛋白表达量于NC组(均P<0.05)。RT-qPCR结果显示,sh-MMP12组MMP-12和PCNA mRNA表达量低于NC组(均P<0.05)。裸鼠移植瘤实验结果显示,sh-MMP 12组肿瘤体积在7、14 d时与NC组比较无统计学差异(均P>0.05),而在21、28 d时与NC组比较明显缩小(均P<0.05);28 d后,sh-MMP12组腋下肿瘤重量低于NC组(P<0.05)。结论:胃癌组织和细胞株SGC-7901中MMP-12表达升高,抑制MMP-12可减缓裸鼠移植瘤生长。

Expression and Significance of LRIG1 Gene in Human Astrocytomas

Objective： LRIG1 gene is a newly found human gene that displays homologies to the Drosophila Kek-1 gene. Previous researches have shown that the LRIG1 gene almost expressed in all human tissues. However, its functions, particularly its functions in human tumors, are still unknown. The goals of the present study are to magnify the expression spectrum of the LRIG1 gene and determine their roles in the oncogenesis. Methods： A triphasic oligonucleotide probe was designed and used to detect the expression level of the LRIG1 gene in 16 astrocytomas and the corresponding tissues around the tumors by in situ hybridization. 11 primary astrocytoma cells were cultured. Among these, the expression level of the LRIG1 gene was checked by in situ hybridization and the expression of the Proliferating Cell Nuclear Antigen （PCNA） protein was detected by immunohistochemistry. Results： The expression of LRIG1 protein was detected in different degree in all the tumors and the surrounding tissues. Compared to the surrounding tissues, the expression of the tumors was lower. The decrease extends from the surrounding tissues to the tumors were correlation to the tumors＇ grades. The primary cultured cells also expressed LRIG1 to various extent and the expression of LRIG1 in the cultures was negatively correlated with the intensity of the PCNA staining. Conclusion： The LRIG1 protein may inhibit the growth of tumors of glial cells and the down-regulation of the LRIG1 gene may be involved in the development and progression of the tumor.

Effect of cis-9,trans-11-conjugated linoleic acid on cell cycle of gastric adenocarcinoma cell line(SGC-7901)

AIM: To determine the effect of cis -9, trans -11-conjugated linoleic acid (c9, t11-CLA) on the cell cycle of gastric cancer cells (SGC-7901) and its possible mechanism in inhibition cancer growth. METHODS: Using cell culture and immunocytochemical techniques, we examined the cell growth, DNA synthesis, expression of PCNA, cyclin A, B(1), D(1), p16(ink4a) and p21(cip/waf1) of SGC-7901 cells which were treated with various c9, t11-CLA concentrations (25, 50, 100 and 200 micromol.L(-1))of c 9, t 11-CLA for 24 and 48h, with a negative control (0.1% ethane). RESULTS: The cell growth and DNA synthesis of SGC-7901 cells were inhibited by c9, t11-CLA.SGC-7901 cells. Eight day after treatment with various concentrations of c9, t11-CLA mentioned above, the inhibition rates were 5.92%, 20.15%, 75.61% and 82.44%, respectively and inhibitory effect of c9, t11-CLA on DNA synthesis (except for 25 micromol.L, 24h) showed significantly less (3)H-TdR incorporation than that in the negative controls (P【0.05 and P【0.01). Immunocytochemical staining demonstrated that SGC-7901 cells preincubated in media supplemented with different c9, t11-CLA concentrations at various times significantly decreased the expressions of PCNA (the expression rates were 7.2-3.0%, 24h and 9.1-0.9% at 48h, respectively), Cyclin A (11.0-2.3%, 24h and 8.5-0.5%,48h), B(1) (4.8-1.8% at 24h and 5.5-0.6% at 48h)and D(1) (3.6-1.4% at 24h and 3.7%-0 at 48h) as compared with those in the negative controls(the expressions of PCNA, Cyclin A, B(1) and D(1) were 6.5% at 24h and 9.0% at 48h, 4.2% at 24h and 5.1% at 48h, 9.5% at 24h and 6.0% at 48h,respectively)(P【0.01), whereas the expressions of P16(ink4a) and P21(cip/waf1), cyclin-dependent kinases inhibitors(CDKI), were increased. CONCLUSION: The cell growth and proliferation of SGC-7901 cell is inhibited by c9, t11-CLA via blocking the cell cycle, with reduced expressions of cyclin A,B(1) and D(1) and enhanced expressions of CDKI(P16(ink4a) and p21(cip/waf1)).

Reversing effect of Tanshinone on malignant phenotypes of human hepatocarcinoma cell line

AIM To study the reversing effect of Chinese drug tanshinone on malignant phenotype of cancer cells.METHODS Human hepatocarcinoma cell line (SMMC-7721) was treated in vitro with 0.5mg/L tanshinone for 4 days, and variation in cell differentiation was detected.RESULTS The morphology of cancer cells was tended toward well differentiation and cell growth was markedly inhibited. BrdU uptake assay and immunohistochemical stain of PCNA showed that the BrdU labeling rate and PCNA positive rate were lower than the controls, but no difference was found statistically as compared with all transretinoic acid. Flow cytometric assay demonstrated that S phase cells decreased and G0/G1 phase cells increased. Expression of c-myc oncogene protein decreased but the c-fos oncogene protein markedly increased.CONCLUSION Tanshinone could reverse the inducing differentiation in human hepatocarcinoma cells (SMMC-7721). It may become a new prospective inducer of cell differentiation to treat cancers.

增殖细胞核抗原在星形细胞瘤中表达的研究

对３３例星形细胞瘤标本进行增殖细胞核抗原（ＰＣＮＡ）抗体免疫组化标记。结果表明：ＰＣＮＡ阳性细胞数随肿瘤的恶性度增高而升高，各级星形细胞瘤的ＰＣＮＡ阳性细胞数除Ⅰ级与Ⅱ级之间无显著差异外（Ｐ＞０．０５），其余各级间都有非常显著的差异（Ｐ＜０．０１），而且Ⅰ、Ⅱ级与Ⅲ、Ⅳ级间有非常显著的差异。提示星形细胞瘤ＰＣＮＡ阳性细胞数与肿瘤的分级有密切的关系，ＰＣＮＡ表达水平能较客观地反映肿瘤的恶性程度，可作为临床评价星形细胞瘤生物学行为及病人预后的参考指标。

喉鳞癌组织中FHIT表达与细胞增殖、转移的关系

背景与目的:脆性组氨酸三联体(fragilehistidinetriad,FHIT)基因定位于染色体3pl4.2,跨越大多数人类基因组的共同脆性部位FRA3B,为一候选的抑癌基因,在包括头颈部鳞状细胞癌在内的许多人类恶性肿瘤中都存在FHIT基因的异常。本研究的目的为探讨喉鳞癌(laryngealsquamouscellcarcinoma,LSCC)组织中FHIT基因蛋白的表达及其与肿瘤细胞增殖与转移的关系。方法:采用免疫组化S法,检测41例喉鳞癌组织及其相对应的喉切缘非癌组织中FHIT、PCNA的表达。结果:非癌组织和喉鳞癌组织中,FHIT阳性率分别为100%(41/41)和46.3%(1941)(P<0.01)。喉鳞癌中,在TNM分期Ⅰ～Ⅱ期和Ⅲ～Ⅳ期组,FHIT阳性率分别为69.6%和16.7%;淋巴结转移阳性和阴性组分别为20.0%和61.5%。以上两组比较均有显著性差异(P<0.05)。非癌和喉鳞癌组织中,PCNA标记指数分别为(9.98±2.34)%和(50.71±13.64)%,两者有极显著性差异(P<0.01)。喉鳞癌中,FHIT与PCNA表达有明显的负相关关系(P<0.05)。结论:FHIT低表达与喉鳞癌细胞增殖及淋巴结转移有关。

肺癌组织中HSG、p21和PCNA的表达及意义

目的探讨细胞增殖抑制基因(HSG)、p21WAF1、增殖细胞核抗原(PCNA)在肺癌中的表达及其相关性。方法采用免疫组化SP法检测92例肺癌(鳞、腺癌)组织中HSG、p21WAF1和PCNA的表达。结果HSG在肺癌组织中的表达与组织学分型、分化程度有关(P<0.01、P<0.001);p21WAF1在肺癌组织中的表达与分化程度、淋巴结转移有关(P<0.001、P<0.01);PCNA在肺癌组织中的表达与分化程度、淋巴结转移有关(P<0.001)。HSG与p21WAF1在肺癌组织中的表达呈正相关(r=0.34,P<0.05);HSG与PCNA在肺癌组织中的表达呈负相关(r=-0.41,P<0.05);p21WAF1与PCNA在肺癌组织中的表达呈负相关(r=-0.49,P<0.05)。结论HSG、p21WAF1和PCNA的表达与肺癌的发生、发展密切相关。

p16和p15及PCNA在子宫颈癌组织中的表达及临床病理意义

目的:研究p16、p15蛋白及增殖细胞核抗原(proliferating cell nuclear antigen,PCNA)在子宫颈癌中的表达特点,并探讨其与病理分级的关系。方法:应用免疫组织化学ElivisionTM二步法检测41例宫颈癌及30例正常宫颈组织中p16、p15及PCNA的表达情况,并结合病理分级进行分析。结果:1)p16和p15蛋白在宫颈癌组织的表达率分别为14·63%(6/41)和17·07%(7/41),明显低于在正常宫颈组织中的表达率100%(30/30)和96·67%(29/30),χ2=8·834,P=0·003;2)p16、p15蛋白阳性表达率与宫颈癌组织的病理学分级有关,p16、p15在宫颈癌Ⅰ级中的阳性表达率28·57%(4/14)、28·57%(4/14),明显高于Ⅱ级18·75%(3/16)、12·50%(2/16),χ2=6·069,P=0·014,也高于Ⅲ级9·09%(1/11)、9·09%(1/11),χ2=7·86,P=0·005;3)宫颈癌组织PCNA阳性表达率95·12%(39/41)及阳性细胞指数(47·97±8·69)%,均明显高于正常对照组的阳性表达率3·33%(1/30)及阳性细胞指数(3·56±0·53)%,χ2=10·773,P=0·001;并且与病理学分级存在相关性。结论:抑癌基因p16、p15的表达缺失在子宫颈癌中同时存在,p16、p15及PCNA检测对于研究宫颈癌的发生、发展和评估子宫颈癌恶性程度具有重要意义。

胃癌组织中p16、p53、Rb和增殖细胞核抗原的表达与临床病理特征的关系

目的：研究胃癌中 p16、 p53、 Rb蛋白及 PCNA表达与临床病理的关系。方法：应用免疫组化 SP法对 63例胃癌组织中 p16、 p53、 Rb和 PCNA进行检测。结果： 63例胃癌组织中 p16、 p53、 Rb蛋白和 PCNA表达阳性率分别为 63.5％、 60.3％、 65.6％和 71.4％。 p16蛋白阳性表达随着肿瘤分化程度降低、恶性程度增加和浸润深度的加深， 其表达的阳性率逐渐降低，而 p53、 Rb蛋白及 PCNA的表达则相反。 p16与 p53、 Rb蛋白表达有明显负相关。结论： p16和 p53、 Rb基因蛋白和 PCNA的检测可作为判断胃癌恶性程度、预测肿瘤转移和预后的参考指标。

PCNA在接受过术前经导管肝动脉栓塞化疗的肝癌组织中的表达及其预后意义

背景与目的:增殖细胞核抗原(proliferating cell nuclear antigen,PCNA)可反映肝细胞癌(以下简称"肝癌")的增殖活性,经导管肝动脉栓塞化疗(transcatheter arterial chemoembolization,TACE)对术后残癌细胞增殖活性影响的报道结果不一。本研究旨在探讨术前TACE对肝癌增殖活性的影响和PCNA在二期切除肝癌复发预后中的意义。方法:选取91例术前TACE及50例未行TACE的肝癌手术切除标本,采用免疫组化方法检测两组标本PCNA的表达情况,分层分析两组PCNA表达的差异,以及术前TACE后二期根治性切除的肝癌中PCNA的表达水平与复发的关系。结果:PCNA表达于肝细胞核中,术前TACE组和未行TACE组的PCNA阳性率分别为67.0%和66.0%(P>0.05),术前TACE组中癌栓、播散结节或肿瘤低分化(Ⅲ～Ⅳ级)者PCNA的表达均明显低于对应分层的未行TACE者,差异有统计学意义(P<0.05)。术前TACE后根治性二期切除患者,复发组与未复发组肿瘤组织中PCNA阳性率分别为77.8%、47.1%,差异有统计学意义(P<0.05)。PCNA阳性组1、3、5年无瘤生存率分别为55.8%、31.8%、23.6%,PCNA阴性组分别为83.2%、62.1%、53.2%,差异有统计学意义(P<0.05)。结论:术前TACE对高侵袭肝癌细胞增殖活性有较好的抑制作用,术前TACE后二期根治性切除肝癌PCNA的表达与患者术后复发转移密切相关。

胃癌组织中PCNA评分和Bc1-2、p53蛋白表达及相互关系

应用ABC免疫组化法研究50例胃癌组织中PCNA评分和Bc1－2、p53蛋白表达。50例胃癌PCNA评分均数为2．400×1．010和Bc1－2、p53蛋白阳性表达率分别为44％及34％；高分化、组织学分级Ⅰ级和未见淋巴结转移胃癌PCNA评分均数和P53蛋白阳性表达率均明显低于低或未分化、组织学分级Ⅲ级和伴淋巴结转移病例；高分化和组织学分级Ⅰ级胃癌Bc1－2蛋白阳性表达率均明显高于未分化和组织学分级Ⅲ级胃癌；Bc1－2蛋白阳性病例PCNA评分均数明显低于Bcl－2蛋白阴性病例，P53蛋白阳性病例PCNA评分明显高于P53蛋白阴性病例。提示PCNA评分和Bc1-2、p53蛋白表达与胃癌发生发展有密切关系，PCNA评分高和p53蛋白阳性病例可能恶性度高和预后差，而Bc1－2蛋白阳性病例恶性度低和预后较好。

胃癌组织P16,P53蛋白和增殖细胞核抗原的表达意义

目的探讨Ｐ１６，Ｐ５３蛋白和增殖细胞核抗原（ｐｒｏｌｉｆｅｒａｔｉｎｇｃｅｌｎｕｃｌｅａｒａｎｔｉｇｅｎ，ＰＣＮＡ）在胃癌的发生、发展中的作用及临床意义．方法应用免疫组织化学方法，对７７例胃癌和癌旁粘膜组织、２１例胃正常组织中Ｐ１６，Ｐ５３蛋白表达产物和ＰＣＮＡ进行检测，并结合临床资料进行分析．结果胃癌组织中Ｐ１６蛋白的阳性率为２０８％（１６／７７），明显低于癌旁粘膜组织５９７％（４６／７７）和胃正常组织９０５％（１９／２１，Ｐ＜００５）；Ｐ５３蛋白与ＰＣＮＡ在胃癌组织中的阳性率为８０５％（６２／７７）和９２２％（７１／７７），明显高于癌旁粘膜组织４１６％（３２／７７），６４９％（５０／７７）和胃正常组织００％（０／２１，Ｐ＜００５）．Ｐ１６，Ｐ５３蛋白和ＰＣＮＡ阳性表达与胃癌组织学类型、浸润深度、分化程度及淋巴结转移有显著性差异（Ｐ＜００５），与患者年龄、性别、肿瘤大小及部位无关（Ｐ＞００１）．结论Ｐ１６，Ｐ５３蛋白和ＰＣＮＡ的异常表达对胃癌的发生发展、恶性程度、淋巴结转移及预后有密切关系和重要临床意义．

星形细胞肿瘤p53蛋白和PCNA免疫组化及其临床病理意义

应用免疫组化和图象分析技术对人脑星形细胞肿瘤中抑癌基因ｐ５３蛋白（４７例）和增殖细胞核抗原（ＰＣＮＡ）（９７例）的定位、分布及反应强度与分级和预后的关系进行了研究。结果显示；３种ｐ５３蛋白抗体的阳性率为２３．４％～６６．７％，其中ＣＭ－１抗体阳性率高于ｐＡｂ１８０１和ｐＡｂ２４０；ｐ５３表达水平在Ⅱ～Ⅳ级高于１级，并与ＰＣＮＡ标记指数之间相关。ＰＣＮＡ反应强度既与分级相关，又与预后相关，对于分析星形细胞瘤增殖活性和恶性程度有重要意义。

肝癌及癌旁肝组织的PCNA免疫组化研究

对３９例肝细胞癌（简称肝癌）及其癌旁肝组织作ＰＣＮＡ免疫组化研究，结果显示：癌与癌旁ＰＣＮＡ阳性率有非常显著差异，癌的阳性率为２５．５％，而癌旁仅１％。肝癌分化越差，ＰＣＮＡ阳性率越高。癌旁以小细胞性肝细胞异型增生（ＬｉｖｅｒＣｅｌｌｄｙｓｐｌａｓｉＬＣＤ）阳性率较高，其阳性率与紧邻肝组织的阳性率有显著差异。肝癌ＰＣＮＡ阳性细胞数与核分裂数之比为２１：１。肝癌ＰＣＮＡ阳性细胞数不成比例地多于核分裂数，认为可能是由于癌细胞ＤＮＡ内复制所致。因而用ＰＣＮＡ来评估肝癌的增殖，可能更符合实际。

人脑胶质瘤组织中nm23与PCNA的表达及其意义

背景与目的:脑胶质瘤极少发生颅外转移,死亡的主要原因是肿瘤的原位复发,因此,通过检测基因表达进一步了解其生物学特性很重要。本研究旨在探讨胶质瘤组织中肿瘤转移抑制基因(non-metastasis,nm23)、增殖细胞核抗原(proliferatingcellnuclearantigen,PCNA)的表达及其对肿瘤恶性程度的判断、患者预后评估和复发预测的意义。方法:用免疫组化SP法测定50例不同恶性程度的胶质瘤组织中nm23、PCNA的表达情况。结果:(1)低度恶性胶质瘤标记指数(labelindex,LI)nm23为3.40±0.27,PCNA为3.60±0.05;高度恶性胶质瘤nm23LI为1.72±0.18,PCNALI为6.20±0.23,有显著性差异(P<0.05);(2)25例低度恶性胶质瘤中nm23阳性14例(56%),PCNA阳性16例(64%);而25例高度恶性胶质瘤中nm23阳性3例(12%),PCNA阳性22例(88%)。低度和高度恶性胶质瘤两组nm23、PCNA表达阳性率有显著性差异(P<0.05);(3)复发组9例,无nm23阳性者(0%),PCNA全部阳性(100%),未复发组8例,4例nm23阳性(50%),4例PCNA阳性(50%),两组nm23、PCNA的表达阳性率均有显著性差异(P<0.05);(4)胶质瘤nm23与PCNA的标记指数呈负相关(r=-0.5335,P<0.001)。结论:(1)nm23的表达随胶质瘤恶性程度增加而下降;(2)PCNA的表达随胶质瘤恶性程度的增加而升高;(3)nm23、PCNA可作为胶质瘤恶?

乳腺浸润性小叶癌中的PCNA和p53蛋白表达及临床意义

目的 :探讨乳腺浸润性小叶癌PCNA、p5 3的表达及意义。 方法 :采用免疫组化S -P法 ,对 5 4例浸润性小叶癌进行检测 ,用有关统计学方法结合随访资料进行分析。结果 :浸润性小叶癌PCNA阳性率为 90 74% (49/5 4) ,PCNA平均指数 5 1 5 0 %± 2 2 49% ,PCNA指数与临床分期、淋巴结转移有密切关系 (P <0 0 1)。随PCNA指数升高 ,浸润性小叶癌患者生存期缩短 (P <0 0 1)。但浸润性小叶癌p5 3阳性率仅为 3 70 % (2 / 5 4)。结论 :1)PCNA可作为反映浸润性小叶癌增殖活性 ,预测预后的重要指标。 2 ) p5 3免疫组化检测不能作为浸润性小叶癌的有用指标 ,需探讨其它的检测方法。 3)进一步显示浸润性小叶癌与来源于导管上皮的乳腺癌的某些生物学特征可能不同。

粉防己碱对人翼状胬肉成纤维细胞体外增殖及增殖细胞核抗原表达的影响

目的:观察粉防己碱(Tet)对体外培养人翼状胬肉成纤维细胞(HPF)增殖的影响。方法:用20、40、80和160μmol/L的Tet作用于体外培养的HPF,24、48及72h后采用MTT法检测细胞生长抑制率,免疫细胞化学法检测HPF增殖细胞核抗原(PCNA)的表达情况。结果:Tet在20、40、80和160μmol/L浓度下作用24、48及72h,能够抑制HPF增殖(F时间=235.632、342.039、586.788和584.667,P均<0.001;F组间=372.672、474.734和389.467,P均<0.001)。Tet干预后PCNA蛋白表达下降(F=185.623,P=0.009)。结论:Tet可抑制翼状胬肉HPF细胞增殖。